Allergy

 
FDA Accepts NDA for Anaphylm™, a Sublingual Epinephrine Film for Treatment of Severe Allergic Reactions
June 17, 2025

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission
June 03, 2025

Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.

Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose
March 28, 2025

Your daily dose of the clinical news you may have missed.

Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study
March 26, 2025

A 5-year study conducted in Germany showed only 7% of adults and 8% of children with severe anaphylaxis received epinephrine.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
March 24, 2025

Your daily dose of the clinical news you may have missed.

Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis
March 18, 2025

Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
March 17, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
March 14, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
March 13, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.